FDA Determines Regulatory Review Period for RAXIBACUMAB Patent Extension Application

Summary

The U.S. Food and Drug Administration (FDA) has determined the regulatory review period for RAXIBACUMAB, a human biological product, in response to a patent extension application submitted to the U.S. Patent and Trademark Office (USPTO), Department of Commerce. This determination is required by law and has been published as a notice.